USA flag logo/image

An Official Website of the United States Government

A Novel Electrospun Vascular Graft

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
96305
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
HL096242
Solicitation Year:
N/A
Solicitation Topic Code:
NHLBI
Solicitation Number:
N/A
Small Business Information
IASIS MOLECULAR SCIENCES, LLC
3305 E MORAN VISTA LN SPOKANE, WA 99223-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: A Novel Electrospun Vascular Graft
Agency: HHS
Contract: 1R43HL096242-01A1
Award Amount: $277,838.00
 

Abstract:

DESCRIPTION (provided by applicant): A novel sulfonated polymer with unique chemically tailorable properties and processing characteristics has shown considerable promise as a thrombo- resistant surface and has been proven to be an effective inhibitor agai nst neutrophil-derived proteases. Phase 1 SBIR testing is proposed to investigate blends of this polymer as vascular graft material. The major specific aims of the proposed research involve the fabrication of a first generation vascular graft from these ma terials using an electrospinning technique and investigating the performance of the graft with blood under flow. The primary objective is to minimize platelet adhesion and activation. This innovative and rational approach to a thrombo-resistant blood condu it is founded on the basis of several different studies that have revealed promising bioapplicable attributes of this polymer family. The end-goal of this Phase 1 SBIR is to develop and identify an inherently non-thrombogenic and anti-inflammatory hydrogel (blend) surface with potential application as a vascular graft and other lifesaving cardiovascular devices. PUBLIC HEALTH RELEVANCE: Cardiovascular disease (CVD) is the leading cause of death and disability for both men and women in the U.S., prese ntly affecting more than 70 million Americans. Overall, more than 6 million hospitalizations occur each year for treatment of cardiovascular diseases. Consequently, the economic impact of CVD on our nation's health care system continues to grow, especially as the population ages. The cost of heart disease and stroke in 2006 (U.S.) was greater than 400 billion, when healthcare cost expenditures and lost productivity from death and disability are accounted for. Under the umbrella of cardiovascular diseases, atherosclerosis-induced peripheral artery disease (PAD), coronary artery disease (CAD) and cerebrovascular disease all result from the primary event of vessel narrowing (stenosis) and/or occlusion due to dysregulated formation of clots and associated infl ammatory events involving smooth muscle cell (SMC) infiltration, neointimal proliferation and maladaptive vascular remodeling. Stenosis and occlusion lead to reduction/loss of antegrade blood flow. For PAD, this may lead to claudication and tissue morbidit y of peripheral extremities, while for CAD this can lead to ischemia and often fatal myocardial infarction and, for cerebrovascular situations, this may lead to stroke. Interventional endovascular and/or surgical treatment to remove thrombus and to reestab lish vascular flow is necessary for clinical management of these diseases. Endovascular treatments involve mechanical approaches like catheter-mediated angioplasty, cryoplasty and enderactomy and, pharmacotherapeutic approaches like transcatheter delivery of thrombolytic, anti-platelet and anti-proliferative drugs. Often these approaches are combined with stenting. Recent years have seen the development of drug eluting stents (DES) where the metal stent surface is coated with a drug-loaded polymer matrix fo r sustained release of therapeutic agents. Surgical approaches involve bypass grafts, many of which are made of synthetic polymers (e.g. ePTFE). For other cardiovascular diseases biomaterials also play an important role. Devices including pacemakers, ventr icular assist devices, and the total artificial heart are used. All of the aforementioned devices depend upon synthetic materials that come into contact with flowing blood. These materials are prone to rapid protein (e.g. fibrinogen, fibrin) deposition, de naturation and subsequent adhesion and activation of blood platelets potentially leading to clot formation and the subsequent activation of coagulation and inflammatory events. In turn, material performance can be compromised necessitating recurring endova scular or surgical procedures. As such, these patients generally require perpetual anticoagulation therapy in order to prevent stroke and/or device failure. Thus, protein- and platelet-resistant blood-contacting interfaces on devices as mentioned above can improve patient outcomes and reduce the overall cost of care. A first-generation synthetic vascular graft is the subject of our investigation. The polymer compositions in these studies are sulfonated block copolymer blends that have demonstrated low thro mbogenicity, good (wet) mechanical properties, and can be electrospun into 3-D vascular graft constructs. Dynamic studies of the electrospun graft (under flow) will be used to understand the materials behavior in blood.

Principal Investigator:

David J. Vachon
5092100736
DAVID.VACHON@AEGISBIOSCIENCES.COM

Business Contact:

David Vachon
Small Business Information at Submission:

IASIS MOLECULAR SCIENCES, LLC
IASIS MOLECULAR SCIENCES, LLC 3305 E MORAN VISTA LN SPOKANE, WA 99223

EIN/Tax ID: 120854212
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No